Am. J. Respir. Crit. Care Med., Volume 158, Number 5, November 1998, 1388-1395

Effects of Dipyridamole and Inhaled Nitric Oxide in Pediatric Patients with Pulmonary Hypertension

JAMES W. ZIEGLER, D. DUNBAR IVY, JAMES W. WIGGINS, JOHN P. KINSELLA, WILLIAM R. CLARKE, and STEVEN H. ABMAN

Department of Pediatrics, University of Colorado School of Medicine, and Children's Hospital, Denver, Colorado; Department of Pediatrics, Brown University School of Medicine, Providence, Rhode Island; and Departments of Anesthesia and Pediatrics, University of Washington School of Medicine, Seattle, Washington

Inhaled nitric oxide (iNO) causes selective pulmonary vasodilation by increasing pulmonary vascular levels of cyclic guanosine monophosphate (cGMP). Dipyridamole, a drug with several putative vasodilator mechanisms, is an inhibitor of cGMP-specific phosphodiesterases (PDE5); it therefore has the potential to increase pulmonary vascular cGMP levels, lower pulmonary vascular resistance, augment iNO-induced pulmonary vasodilation, and attenuate excessive pulmonary vasoreactivity. To test dipyridamole in the pulmonary circulation, we studied pediatric patients undergoing cardiac catheterization who had severe resting pulmonary hypertension (Group 1; n = 11) or exaggerated acute hypoxia-induced pulmonary vasoconstriction (Group 2; n = 4). In Group 1, we compared the effects of iNO (20 ppm), dipyridamole (0.6 mg/kg), and combined treatments (iNO + dipyridamole) on pulmonary and systemic hemodynamics. In Group 2 we measured the pulmonary and systemic effects of dipyridamole while the patients were breathing room air and hypoxic gas mixtures (FI_O2 = 0.16). One patient in Group 1 had a hypotensive response to dipyridamole and was exluded from study. In the remaining 12 studies done on 10 patients, iNO caused a selective decrease in mean pulmonary artery pressure () and indexed pulmonary vascular resistance (PVRI) without affecting mean aortic pressure () or indexed systemic vascular resistance (SVRI). Dipyridamole decreased PVRI to similar values as did iNO, but this effect was primarily due to an increase in cardiac index (CI), and was not associated with any change in , and was associated with a decrease in and SVRI. In comparison with individual treatments, combined therapy (iNO + dipyridamole) did not augment pulmonary vasodilation in the group as a whole; however, in 50% of patients, combined therapy decreased PVRI by 20% more than did iNO or dipyridamole alone. In Group 2,  and the pulmonary-to-systemic resistance ratio (Rp/Rs) increased to suprasystemic levels during acute hypoxia. Pretreatment with dipyridamole blunted the increase in and Rp/Rs during repeat hypoxia, keeping at a subsystemic level and Rp/Rs < 1. We conclude that: (1) dipyridamole nonselectively reduces PVRI, primarily through an increase in CI; (2) in combination with iNO, dipyridamole augments the decrease in PVRI in some patients; and (3) dipyridamole blunts the severity of acute hypoxic pulmonary vasoconstriction in children with exaggerated hypoxic pressor responses.

This article has been cited by other articles:

				Q. Zhao, Z. Liu, Z. Wang, C. Yang, J. Liu, and J. Lu Effect of Prepro-Calcitonin Gene-Related Peptide Expressing Endothelial Progenitor Cells on Pulmonary Hypertension Ann. Thorac. Surg., August 1, 2007; 84(2): 544 - 552. [Abstract] [Full Text] [PDF]

				D J Fox and R S Khattar Pulmonary arterial hypertension: classification, diagnosis and contemporary management Postgrad. Med. J., November 1, 2006; 82(973): 717 - 722. [Full Text] [PDF]

				D. A Calhoun, S N. Murthy, B. G Bryant, S. A Luedtke, and V. Bhatt-Mehta Recent Advances in Neonatal Pharmacotherapy Ann. Pharmacother., April 1, 2006; 40(4): 710 - 719. [Abstract] [Full Text] [PDF]

				S. Jaillard, B. Larrue, P. Deruelle, A. Delelis, T. Rakza, G. Butrous, and L. Storme Effects of Phosphodiesterase 5 Inhibitor on Pulmonary Vascular Reactivity in the Fetal Lamb. Ann. Thorac. Surg., March 1, 2006; 81(3): 935 - 942. [Abstract] [Full Text] [PDF]

				A. L. Trachte, E. B. Lobato, F. Urdaneta, P. J. Hess, C. T. Klodell, T. D. Martin, E. D. Staples, and T. M. Beaver Oral Sildenafil Reduces Pulmonary Hypertension After Cardiac Surgery Ann. Thorac. Surg., January 1, 2005; 79(1): 194 - 197. [Abstract] [Full Text] [PDF]

				P. M. Mourani, D. D. Ivy, D. Gao, and S. H. Abman Pulmonary Vascular Effects of Inhaled Nitric Oxide and Oxygen Tension in Bronchopulmonary Dysplasia Am. J. Respir. Crit. Care Med., November 1, 2004; 170(9): 1006 - 1013. [Abstract] [Full Text] [PDF]

				F. Urdaneta, J. L. Willert, T. Beaver, B. Naik, D. S. Kirby, and E. B. Lobato Effects of a New Phosphodiesterase Enzyme Type V Inhibitor (UK 343-664) Versus Milrinone in a Porcine Model of Acute Pulmonary Hypertension Ann. Thorac. Surg., October 1, 2004; 78(4): 1433 - 1437. [Abstract] [Full Text] [PDF]

				D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]

				M. R. Bonnell, F. Urdaneta, D. S. Kirby, N. R. Valdez, T. M. Beaver, and E. B. Lobato Effects of sildenafil analogue UK 343-664 on a porcine model of acute pulmonary hypertension Ann. Thorac. Surg., January 1, 2004; 77(1): 238 - 242. [Abstract] [Full Text] [PDF]

				L. Foubert, D. De Wolf, K. Reyntjens, Y. Van Belleghem, F. De Somer, G. Van Nooten, and E. Mortier Intermittent Nitric Oxide Combined with Intravenous Dipyridamole in a Piglet Model of Acute Pulmonary Hypertension Anesth. Analg., November 1, 2003; 97(5): 1497 - 1500. [Abstract] [Full Text] [PDF]

				S. M. Black, L. S. Sanchez, E. Mata-Greenwood, J. M. Bekker, R. H. Steinhorn, and J. R. Fineman sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, November 1, 2001; 281(5): L1051 - L1057. [Abstract] [Full Text] [PDF]

				R. F. Lodato Viagra for Impotence of Pulmonary Vasodilator Therapy? Am. J. Respir. Crit. Care Med., February 1, 2001; 163(2): 312 - 313. [Full Text]

				V. G. Nielsen Nitric Oxide Decreases Coagulation Protein Function in Rabbits as Assessed by Thromboelastography Anesth. Analg., February 1, 2001; 92(2): 320 - 323. [Abstract] [Full Text] [PDF]

				Z. Y. Jiang, T. Costachescu, M. Derouin, and G. Blaise Treatment of pulmonary hypertension during surgery with nitric oxide and vasodilators Can J Anesth, June 1, 2000; 47(6): 552 - 555. [Abstract] [Full Text] [PDF]

				V. G. NIELSEN, M. S. BAIRD, L. CHEN, and S. MATALON DETANONOate, a Nitric Oxide Donor, Decreases Amiloride-sensitive Alveolar Fluid Clearance in Rabbits Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): 1154 - 1160. [Abstract] [Full Text]